ERBB2 and breast carcinoma: As various clinical trials and new treatment concepts continue to emerge, its treatment mode has also changed from the single chemotherapy to the current neoadjuvant chemotherapy which based on different molecular subtypes of breast cancer, such as neoadjuvant anti-human epidermal growth factor receptor 2 (HER-2) targeted therapy combined with chemotherapy and neoadjuvant endocrine therapy (4).